Abstract:Proc Amer Assoc Cancer Res, Volume 45, 2004 1912 Histomorphometric evaluation of prostate cancer (CaP) bone metastases reveals a mixture of osteoblastic and osteolytic lesions. The receptor activator of NFκB ligand (RANKL)/RANK/osteoprotegerin (OPG) group of proteins form a critical system that control bone remodeling equilibrium and has been shown to be active in CaP bone metastases. RANKL induces osteolysis upon binding to RANK, and OPG, a soluble decoy receptor, blocks RANKL pro-osteoclastic activity. The ratio of RANKL/OPG is important in regulating the ultimate balance between bone formation and bone resorption. To determine if the presence of CaP bone metastases alters the ratio of soluble RANKL to OPG we measured levels of these factors in serum of men without bone metastases (n=24) or with bone metastases (n=50) using commercially available ELISAs. Of the men without bone metastases, 11 had early recurrent disease (PSA rising after primary therapy) and 13 had advanced disease (highly elevated PSA levels). Of the men with bone metastases, 4 had early recurrent disease and 46 had advanced disease. Levels of sRANKL were 0.69±0.21 pmol/l and 0.32±0.07 pmol/l in patients without bone metastases vs. those with bone metastases, respectively (p=0.05). Levels of OPG were and 5.45±0.66 pg/ml and 9.32±1.51 pg/ml in patients without bone metastases vs. those with bone metastases, respectively (p=0.10). The ratio of sRANKL/OPG was decreased by 71% in men with bone metastases (p=0.007); the altered ratio is the result of an increase of ∼50% in OPG concentration and ∼50% decrease in sRANKL concentration. It has been reported that osteoclastic factors such as interleukin-6 (IL-6) may promote RANKL expression. IL-6 has been reported to be increased with advanced CaP; therefore, we measured serum levels of IL-6 and its soluble receptor (sIL-6R). Serum IL-6 increased from 4.95±1.50 pg/ml in men without bone metastases to 29.12±8.83 pg/ml in men with bone metastases (p=0.07); whereas sIL-6R was not significantly different between these groups. A caveat in interpreting our results is that serum levels of sRANKL, OPG, IL-6 and sIL-6R may not reflect the levels and activities of these factors in the bone. In conclusion, bone remodeling and the development of osteoblastic or osteolytic lesions in CaP patients is under the control of multiple factors. Increased levels of serum IL-6 suggest that there is stimulation of osteoclastic activity in bone, as demonstrated on histomorphometry of CaP bone metastases, but the decrease in the sRANKL/OPG ratio is consistent with inhibition of osteoclastogenesis and a shift towards an osteoblastic phenotype associated with CaP bone metastases.

Abnormal Bone Remodeling Process Is Due To An Imbalance In The Receptor Activator Of Nuclear Factor-Kappa B Ligand (Rankl)/Osteoprotegerin (Opg) Axis In Patients With Solid Tumors Metastatic To The Skeleton

Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Differential Expression of the RANKL/RANK/OPG System is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer

Prostate cancer bone metastases are associated with a decreased serum sRANKL/OPG ratio

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.

Expression Profile of Receptor Activator of Nuclear-Κb (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer.

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

[Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor]

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Potential Role of the OPG/RANK/RANKL Axis in Prostate Cancer Invasion and Bone Metastasis

Targeting RANK/RANKL in the treatment of solid tumours and myeloma

Bone Turnover Markers As Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

Value of C-Telopeptide-Cross-Linked Type I Collagen, Osteocalcin, Bone-Specific Alkaline Phosphatase and Procollagen Type I N-Terminal Propeptide in the Diagnosis and Prognosis of Bone Metastasis in Patients with Malignant Tumors

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment

Osteopontin As a Multifaceted Driver of Bone Metastasis and Drug Resistance

RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

Prostate Cancer Cells Induce Osteoclastogenesis And Bone Resorption Through Rankl-Independent Interleukin-8 (Il-8) And Monocyte Chemoattractant Protein-1 (Mcp-1) Production